Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.
When cancer arises in the body, it starts with tumor cells that rapidly grow and divide and eventually spread.
As part of its ongoing efforts to eradicate childhood cancers, the St. Baldrick's Foundation has awarded University of Colorado Cancer Center member Kelly Faulk, MD, a St. Baldrick's Scholar grant to investigate a new method for treating infant leukemia.
Chemotherapy sucks. The treatments generally have awful side effects, and it's no secret that the drugs involved are often toxic to the patient as well as their cancer.
A new study led by researchers at the American Cancer Society (ACS) reports nearly 123,000 cancer deaths, or close to 30 percent of all cancer deaths, were from cigarette smoking in the United States in 2019, leading to more than two million Person-Years of Lost Life (PYLL) and nearly $21 billion in annual lost earnings. These losses were disproportionately higher in states with weaker tobacco control policies in the South and Midwest. The results were published today in the International Journal of Cancer.
Patients seeking to purchase chemotherapy drugs online face a confusing array of websites, over half of which potentially operate unsafely or illegally, finds a new study in the July 2022 issue of JNCCN-; Journal of the National Comprehensive Cancer Network.
A biochemist from RUDN and IBMC has found a way to protect healthy leukocytes during leukemia chemotherapy. Small nitrogen-containing polyamine molecules give the necessary protection.
An article published in the journal Nature Communications describes a specific metabolic adaptation in some patients with acute myeloid leukemia affected by tandem mutations in the FLT3 gene.
The Damon Runyon Cancer Research Foundation has named five new Damon Runyon Clinical Investigators.
Natural compounds often have promising therapeutic potential but their use to treat diseases is hampered due to toxicity or non-desirable effects.
Understanding why and how chemotherapy resistance occurs is a major step toward optimizing treatments for cancer.
On Tuesday, June 7, Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, will present the long-term results of a phase 2 clinical trial combining crenolanib, a second-generation FLT3 inhibitor, with standard intensive chemotherapy for treatment of adults with newly diagnosed FLT3-mutant acute myeloid leukemia (AML).
Patients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute can help patients and their physicians weigh benefits and risks of each option.
Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia (AML), a type of blood cancer, and proved effective in animal models of the disease, according to a preclinical study by investigators at Weill Cornell Medicine.
Researchers investigate the risk factors present in individuals suffering from hematological malignancies and COVID-19.
The National Comprehensive Cancer Network today announced the recipients of 2022 awards for both internal and external champions advancing NCCN's mission and helping all people with cancer to live better lives.
Researchers at The University of Texas MD Anderson Cancer Center have discovered that adolescent and young adult (AYA) cancer survivors of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) have reduced long-term survival rates compared to their peers without cancer.
South Australian scientists have made a significant breakthrough in overcoming drug resistance in acute myeloid leukemia (AML), a rare and devastating blood cancer that kills most patients within a few years.
Massachusetts General Hospital researchers have developed a novel treatment strategy that has the potential to bring the life-saving benefits of chimeric antigen receptor T-cell therapy (CAR T) to patients with acute myeloid leukemia (AML) the most common form of leukemia in adults.
Researchers utilized a CRISPR/Cas9 system to evaluate the usage of tRNA by deleting two tRNA genes from the genomes of hyper hepatocellular carcinoma and human near-haploid chronic myeloid leukemia cells.
Northwestern Medicine investigators have discovered a novel signaling pathway activated by interferons, a group of immune system proteins, that suppresses the anti-tumor response of interferons in patients with a particular type of blood cancer, according to findings published in Nature Communications.